Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 12/2000

Content (6 Articles)

ORIGINAL ARTICLE

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens

Craig L. Slingluff Jr., Teresa A. Colella, Lee Thompson, D. David Graham, Jonathan C.A. Skipper, Jennifer Caldwell, Larry Brinckerhoff, David J. Kittlesen, Donna H. Deacon, Correen Oei, Nancy L. Harthun, Eric L. Huczko, Donald F. Hunt, Tim L. Darrow, Victor H. Engelhard

ORIGINAL ARTICLE

Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression

P. Jimenez, J. Cantón, A. Concha, T. Cabrera, M. Fernández, L. M. Real, A. García, A. Serrano, F. Garrido, F. Ruiz-Cabello

ORIGINAL ARTICLE

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

Daming Shan, Jeffrey A. Ledbetter, Oliver W. Press

ORIGINAL ARTICLE

Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma

Jesper Max Tordsson, Lennart Göran Ohlsson, Lars Bertil Abrahmsén, Pia Jasmine Karlström, Peter Anders Lando, Thomas Nils Brodin

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine